View in EDS PDF Full Text

Experiencia clínica inicial con ribociclib en cáncer de mama avanzado RH+/HER2− en Uruguay.

Saved in:
Bibliographic Details
Title: Experiencia clínica inicial con ribociclib en cáncer de mama avanzado RH+/HER2− en Uruguay.
Alternate Title: Initial clinical experience with ribociclib in advanced HR+/HER2− breast cancer in Uruguay.
Authors: Camejo-Martínez, Natalia1 ncam3@yahoo.com, Strazzarino-Peluffo, Noelia1, Amarillo-Hernández, Dahiana1, Castillo-Leska, Cecilia1, Krygier-Waltier, Gabriel1
Source: Revista Medica del IMSS. may/jun2026, Vol. 64 Issue 3, p1-7. 7p.
Subjects: CYCLIN-dependent kinase inhibitors, HORMONE receptor positive breast cancer, TREATMENT effectiveness, METASTATIC breast cancer, ADVERSE health care events, HORMONE therapy, SAFETY
Geographic Terms: URUGUAY
Abstract (English): Background: Ribociclib improves progression-free and overall survival (PFS and OS) in women with advanced HR+/HER2− breast cancer (BC), but real-world evidence in Uruguay is limited. Objective: To describe the clinical characteristics, outcomes, and safety profile of women with advanced HR+/ HER2− breast cancer treated with ribociclib plus hormone therapy in Uruguay. Materials and methods: Observational, retrospective study. Demographic and clinical variables, type of hormone therapy, treatment duration, and adverse events were analyzed. Results: A total of 54 patients from public and private institutions were included, with a median age of 60 years. 67% relapsed after adjuvant treatment. Bone was the most common metastatic site (72%). Ribociclib was administered as first-line treatment in 81% of cases, and combined with aromatase inhibitors in 63%. The mean OS was 41.6 months and the mean PFS was 30 months; medians were not reached. Neutropenia was the most frequent adverse event (66%), followed by gastrointestinal toxicity (nausea 33%, diarrhea 28%) and skin toxicity (16%). One death due to pulmonary embolism was recorded, and QTc prolongation was documented in 5.6% of patients. Dose reduction was required in 20%, and one patient discontinued treatment due to skin toxicity. Conclusion: Ribociclib was well tolerated, with a safety profile consistent with the literature. This study provides relevant local evidence and supports its use in real-world settings. Longer follow-up is needed to more accurately assess OS and PFS outcomes. [ABSTRACT FROM AUTHOR]
Abstract (Spanish): Introducción: el ribociclib mejora la supervivencia libre de progresión y global (SVLP y SVG) en mujeres con cáncer de mama (CM) avanzado RH+/HER2−, pero la evidencia en la vida real es limitada en Uruguay. Objetivo: describir las características clínicas, evolución y perfil de seguridad de mujeres con CM avanzado RH+/ HER2− tratadas con ribociclib más hormonoterapia en Uruguay. Material y métodos: estudio observacional y retrospectivo. Se analizaron variables demográficas, clínicas, tipo de hormonoterapia, duración del tratamiento y eventos adversos (EA). Resultados: se incluyeron 54 pacientes de instituciones públicas y privadas, con una mediana de edad de 60 años. El 67% recayó tras tratamiento adyuvante. El sitio metastásico más común fue el óseo (72%). El ribociclib se administró en primera línea en 81% de los casos, y en combinación con inhibidores de aromatasa en 63%. La media de SVG fue de 41.6 meses y la de SVLP de 30 meses, sin alcanzarse la mediana en ninguno de los casos. La neutropenia fue el EA más frecuente (66%), seguida de toxicidad digestiva (náuseas 33%, diarrea 28%) y cutánea (16%). Se registró una muerte por tromboembolismo pulmonar y prolongación del QTc en el 5.6%. El 20% requirió reducción de dosis y una paciente suspendió el tratamiento por toxicidad cutánea. Conclusión: el ribociclib fue bien tolerado, con un perfil de toxicidad acorde a la literatura. Este estudio aporta evidencia local relevante y respalda su uso en escenarios reales. Se requiere seguimiento más prolongado para evaluar SVG y SVLP con mayor precisión. [ABSTRACT FROM AUTHOR]
Copyright of Revista Medica del IMSS is the property of Direccion de Prestaciones Medicas - IMSS and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: MedicLatina
FullText Links:
  – Type: pdflink
Text:
  Availability: 0
Header DbId: lth
DbLabel: MedicLatina
An: 193665394
AccessLevel: 6
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Experiencia clínica inicial con ribociclib en cáncer de mama avanzado RH+/HER2− en Uruguay.
– Name: TitleAlt
  Label: Alternate Title
  Group: TiAlt
  Data: Initial clinical experience with ribociclib in advanced HR+/HER2− breast cancer in Uruguay.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22Camejo-Martínez%2C+Natalia%22">Camejo-Martínez, Natalia</searchLink><relatesTo>1</relatesTo><i> ncam3@yahoo.com</i><br /><searchLink fieldCode="AR" term="%22Strazzarino-Peluffo%2C+Noelia%22">Strazzarino-Peluffo, Noelia</searchLink><relatesTo>1</relatesTo><br /><searchLink fieldCode="AR" term="%22Amarillo-Hernández%2C+Dahiana%22">Amarillo-Hernández, Dahiana</searchLink><relatesTo>1</relatesTo><br /><searchLink fieldCode="AR" term="%22Castillo-Leska%2C+Cecilia%22">Castillo-Leska, Cecilia</searchLink><relatesTo>1</relatesTo><br /><searchLink fieldCode="AR" term="%22Krygier-Waltier%2C+Gabriel%22">Krygier-Waltier, Gabriel</searchLink><relatesTo>1</relatesTo>
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22Revista+Medica+del+IMSS%22">Revista Medica del IMSS</searchLink>. may/jun2026, Vol. 64 Issue 3, p1-7. 7p.
– Name: Subject
  Label: Subjects
  Group: Su
  Data: <searchLink fieldCode="DE" term="%22CYCLIN-dependent+kinase+inhibitors%22">CYCLIN-dependent kinase inhibitors</searchLink><br /><searchLink fieldCode="DE" term="%22HORMONE+receptor+positive+breast+cancer%22">HORMONE receptor positive breast cancer</searchLink><br /><searchLink fieldCode="DE" term="%22TREATMENT+effectiveness%22">TREATMENT effectiveness</searchLink><br /><searchLink fieldCode="DE" term="%22METASTATIC+breast+cancer%22">METASTATIC breast cancer</searchLink><br /><searchLink fieldCode="DE" term="%22ADVERSE+health+care+events%22">ADVERSE health care events</searchLink><br /><searchLink fieldCode="DE" term="%22HORMONE+therapy%22">HORMONE therapy</searchLink><br /><searchLink fieldCode="DE" term="%22SAFETY%22">SAFETY</searchLink>
– Name: SubjectGeographic
  Label: Geographic Terms
  Group: Su
  Data: <searchLink fieldCode="DE" term="%22URUGUAY%22">URUGUAY</searchLink>
– Name: Abstract
  Label: Abstract (English)
  Group: Ab
  Data: Background: Ribociclib improves progression-free and overall survival (PFS and OS) in women with advanced HR+/HER2− breast cancer (BC), but real-world evidence in Uruguay is limited. Objective: To describe the clinical characteristics, outcomes, and safety profile of women with advanced HR+/ HER2− breast cancer treated with ribociclib plus hormone therapy in Uruguay. Materials and methods: Observational, retrospective study. Demographic and clinical variables, type of hormone therapy, treatment duration, and adverse events were analyzed. Results: A total of 54 patients from public and private institutions were included, with a median age of 60 years. 67% relapsed after adjuvant treatment. Bone was the most common metastatic site (72%). Ribociclib was administered as first-line treatment in 81% of cases, and combined with aromatase inhibitors in 63%. The mean OS was 41.6 months and the mean PFS was 30 months; medians were not reached. Neutropenia was the most frequent adverse event (66%), followed by gastrointestinal toxicity (nausea 33%, diarrhea 28%) and skin toxicity (16%). One death due to pulmonary embolism was recorded, and QTc prolongation was documented in 5.6% of patients. Dose reduction was required in 20%, and one patient discontinued treatment due to skin toxicity. Conclusion: Ribociclib was well tolerated, with a safety profile consistent with the literature. This study provides relevant local evidence and supports its use in real-world settings. Longer follow-up is needed to more accurately assess OS and PFS outcomes. [ABSTRACT FROM AUTHOR]
– Name: Abstract
  Label: Abstract (Spanish)
  Group: Ab
  Data: Introducción: el ribociclib mejora la supervivencia libre de progresión y global (SVLP y SVG) en mujeres con cáncer de mama (CM) avanzado RH+/HER2−, pero la evidencia en la vida real es limitada en Uruguay. Objetivo: describir las características clínicas, evolución y perfil de seguridad de mujeres con CM avanzado RH+/ HER2− tratadas con ribociclib más hormonoterapia en Uruguay. Material y métodos: estudio observacional y retrospectivo. Se analizaron variables demográficas, clínicas, tipo de hormonoterapia, duración del tratamiento y eventos adversos (EA). Resultados: se incluyeron 54 pacientes de instituciones públicas y privadas, con una mediana de edad de 60 años. El 67% recayó tras tratamiento adyuvante. El sitio metastásico más común fue el óseo (72%). El ribociclib se administró en primera línea en 81% de los casos, y en combinación con inhibidores de aromatasa en 63%. La media de SVG fue de 41.6 meses y la de SVLP de 30 meses, sin alcanzarse la mediana en ninguno de los casos. La neutropenia fue el EA más frecuente (66%), seguida de toxicidad digestiva (náuseas 33%, diarrea 28%) y cutánea (16%). Se registró una muerte por tromboembolismo pulmonar y prolongación del QTc en el 5.6%. El 20% requirió reducción de dosis y una paciente suspendió el tratamiento por toxicidad cutánea. Conclusión: el ribociclib fue bien tolerado, con un perfil de toxicidad acorde a la literatura. Este estudio aporta evidencia local relevante y respalda su uso en escenarios reales. Se requiere seguimiento más prolongado para evaluar SVG y SVLP con mayor precisión. [ABSTRACT FROM AUTHOR]
– Name: AbstractSuppliedCopyright
  Label:
  Group: Ab
  Data: <i>Copyright of Revista Medica del IMSS is the property of Direccion de Prestaciones Medicas - IMSS and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.)
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=lth&AN=193665394
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.5281/zenodo.18715279
    Languages:
      – Code: spa
        Text: Spanish
    PhysicalDescription:
      Pagination:
        PageCount: 7
        StartPage: 1
    Subjects:
      – SubjectFull: CYCLIN-dependent kinase inhibitors
        Type: general
      – SubjectFull: HORMONE receptor positive breast cancer
        Type: general
      – SubjectFull: TREATMENT effectiveness
        Type: general
      – SubjectFull: METASTATIC breast cancer
        Type: general
      – SubjectFull: ADVERSE health care events
        Type: general
      – SubjectFull: HORMONE therapy
        Type: general
      – SubjectFull: SAFETY
        Type: general
      – SubjectFull: URUGUAY
        Type: general
    Titles:
      – TitleFull: Experiencia clínica inicial con ribociclib en cáncer de mama avanzado RH+/HER2− en Uruguay.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Camejo-Martínez, Natalia
      – PersonEntity:
          Name:
            NameFull: Strazzarino-Peluffo, Noelia
      – PersonEntity:
          Name:
            NameFull: Amarillo-Hernández, Dahiana
      – PersonEntity:
          Name:
            NameFull: Castillo-Leska, Cecilia
      – PersonEntity:
          Name:
            NameFull: Krygier-Waltier, Gabriel
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 05
              Text: may/jun2026
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-print
              Value: 04435117
          Numbering:
            – Type: volume
              Value: 64
            – Type: issue
              Value: 3
          Titles:
            – TitleFull: Revista Medica del IMSS
              Type: main
ResultId 1